GHRS
NASDAQ HealthcareGH Research PLC - Ordinary Shares
Biotechnology
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
�� 市场数据
| 价格 | $18.34 |
|---|---|
| 成交量 | 138,502 |
| 市值 | 1.14B |
| 贝塔系数 | 1.000 |
| RSI（14日） | 89.0 超买 |
| 200日均线 | $14.41 |
| 50日均线 | $15.21 |
| 52周最高 | $19.51 |
| 52周最低 | $8.66 |
| Forward P/E | -9.99 |
| Price / Book | 4.07 |
🎯 投资策略评分
GHRS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (91/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (8/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 GHRS in your text
粘贴任何文章、记录或帖子 — 工具将提取 GHRS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.